Human BCR/ABL gene T315I mutation detection and analysis

Abstract

The invention provides a kit for human BCR / ABLT 315 I mutation and a preparation method and application thereof. The application of the kit has guiding significance for CML and Ph+ALL drug resistancescreening and clinical scientific drug use, wherein the ABL T315I mutation of BCR-ABL fusion gene is clinically used as a main indicator for CML and Ph+ALL drug treatment guidance.

Description

technical field [0001] The invention relates to gene detection technology in the field of molecular biology, in particular to the detection and analysis of human BCR-ABL gene T315I mutation, and provides a kit for human BCR / ABLT315I mutation. Background technique [0002] The Philadelphia chromosome is t(9;22)(q34;q11) formed by the mutual translocation of chromosomes 9 and 22, which encodes an abnormal protein "BCR-ABL" fusion protein. Due to the different breaking points of ABL on chromosome 9, three fusion genes were produced, encoding three fusion proteins P190, P210, and P230 with different molecular weights. Among them, 95% of chronic myelogenous leukemia (CML) and 20%-40% of acute lymphoblastic leukemia (ALL) can detect the characteristic Ph chromosome and its molecular marker BCR-ABL fusion gene. [0003] CML is a malignant proliferative disease of the hematopoietic system. Its global incidence rate is 1.6 / 100,000 people, and the incidence rate in my country is 0.39...

AI Technical Summary

Problems solved by technology

When the dose of TKI is increased or the second-generation TKI is replaced, most of the mutant patients are clinically effective for the above changes, but patients with BCR / ABLT315I mutations are not effective for the above drugs

Images